Intravenous regional administration of corticosteroids in juvenile chronic arthritis

Tägil, Magnus; Reimertz, Jan; Elborgh, Renate; Kopylov, Philippe

Published in:
Acta Orthopaedica Scandinavica

2004

Link to publication

Citation for published version (APA):

Total number of authors:
4

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Intravenous regional administration of corticosteroids in juvenile chronic arthritis

Magnus Tägil¹, Jan Reimertz³, Renate Elborgh² and Philippe Kopylov¹

¹Hand and Upper Extremity Unit, Department of Orthopedics, ²Department of Rheumatology, Lund University Hospital, SE-221 85 Lund, Sweden, ³Department of Orthopedics, Växjö, Sweden
Correspondence MT: magnus.tagil@ort.lu.se
Submitted 03-10-13. Accepted 03-11-27

Background  Treatment of juvenile chronic arthritis patients with longstanding multiple joint or tendon involvement that is resistant to medication remains a challenge. For 20 years, we have been treating these severely ill patients with intravenous regional glucocorticoids (a modified Bier’s block).

Patients and methods  Since 1996, all juvenile chronic arthritis patients have been followed prospectively by an occupational therapist who has registered the grip strength and range of motion at an average of 6 months after treatment.

Results  In 22/40 wrists and hands, increased grip strength was recorded. The mean grip strength increased for the whole group from 47 to 59 N and the flexion lag decreased.

Interpretation  The effect of intravenous regional steroid treatment may be limited from a long-term perspective, but in our series, half of the patients showed a considerable improvement after 6 months. Surgical synovectomy can be postponed and perhaps even be omitted.

Sometimes tenosynovitis or arthrosynovitis in juvenile chronic arthritis persists despite systemic medication and local corticosteroid injections. Since the 1980s, we have been using intravenous regional corticosteroids in this situation for treatment of both upper and lower extremities. Here we describe this treatment for the hands in juvenile patients and evaluate the mid-term effect in terms of grip strength and range of motion.
tiple joint swellings and/or tenosynovitis that had not responded to alterations in systemic medication and/or locally administered corticosteroids. The mean age was 10 (6–18) years. All patients had a juvenile chronic arthritis. 12 children had seropositive polyarticular, 7 had seronegative polyarticular, 1 oligoarticular and 1 mixed connective tissue disease (MCTD). The mean C-reactive protein value at the time of treatment was 60 (SD 53) mg/L and at follow-up 34 (SD 29) mg/L, the mean hemoglobin value was 111 (SD 15) g/L and 116 (SD 12) g/L, and the thrombocyte concentration 474 (SD 145) × 10^9/L and 423 (SD 134) × 10^9/L, respectively. The follow-up examinations were made at a mean of 6 (4–12) months after treatment.

If the patients had further surgical treatment in the same hand or arm, the examination before this procedure was chosen as the follow-up examination, regardless of time point. The patients were examined by an occupational therapist preoperatively and at the follow-up. Grip strength was measured using the Grippit meter (Nordenskjöld and Grimby 1993), and extension and flexion deficits were measured. Mean grip strength was chosen as the main outcome parameter. For statistical analysis, the mean value was calculated for each patient in bilateral cases and each hand in unilateral cases. Paired t-test was used for statistical analysis.

Results

No adverse effects were noted. In 22/40 hands, increased grip strength was recorded. The mean grip strength increased for the whole group from 47 to 59 N (p = 0.01, paired t-test; Table). The flexion lag decreased from 10 to 6 mm (p = 0.04), whereas the extension lag was unchanged.

Within the first year, 7 patients had repeated surgical treatment. In 4 patients, the intravenous regional steroid treatment was repeated and in 5 patients an open or transarthroscopic teno- and/or arthroscopy was performed. 1 patient has since been operated with a wrist arthrodesis and another with bilateral elbow prostheses. In total, another 25 operations (0–4) have been done in the upper extremities in these 21 patients to date.

Discussion

In the early stages of joint or soft tissue swelling in juvenile chronic arthritis, medication and sometimes splints are the treatment of choice and the synovitis can often remit. Apart from oral administration, corticosteroids can be administered locally as injections into tendon-sheets or into joints. Intraarticular injections are efficient into a limited amount of joints and lead to full remission after 6 months in 80% of patients, so that oral medication may be discontinued (Padeh and Passwell 1998). When multiple joints and tendons are involved (Figure 2), the total dose becomes high. Systemic side effects may also appear after local treatment and correct deposition into multiple tendon sheets can be difficult to achieve. High-dose pulsed intravenous treatment has also been used in children (Adebajo and Hall 1998). Gastrointestinal hemorrhage, arrhythmias and avascular necrosis of the hip have, however, been reported in adults treated by this method. Surgical arthro- and tenosynovectomy reduces pain effectively, but is often followed by decreased mobility (Hanff et al. 1990) and requires the young patient to be able to cope
with an often intense postoperative training. The preventive effect in the long term is unclear.

As an alternative approach, when everything else has been tried, corticosteroids can be administered as intravenous regional treatment analogous to a Biers block, whereby corticosteroids are injected instead of local anestheticum. The method has been described in adult rheumatoid patients and good short-term effects have been reported (Jelinek et al. 1991, McCarthy et al. 1993, Bengtsson et al. 1998). In the latter study, local anesthetic was used as placebo control and was as rewarding as cortisone for up to 6 weeks.

Our hospital is the national centre for juvenile chronic arthritis in Sweden, and patients come from all over the country for medical treatment and surgery. The children travel back home before full effect has been achieved, which makes a complete and standardized short-term follow-up and outcome analysis difficult. Interpretation of our mid-term results in the juvenile patients is difficult. Half of the patients showed no increase in, or even a reduction in grip strength at follow-up and we do not know how these patients would have been without treatment. The other half of the patients showed a substantial improvement. Also, in this group we do not know whether this reflects a spontaneous remission of the disease or an actual effect of the treatment. For this reason, the results can only be roughly compared to historical data from synovectomy series, the operation that would have been performed on these patients 20 years ago (Hanff et al. 1990).

The mode of action of the cortisone can only be hypothesized. The local anesthetic in a Bier block binds to the tissue and only small amounts are released into the blood stream after the block is released. No detectable plasma concentration of cortisone can be traced 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991). However, suppression of endogenous cortisol production was found 24 hours after intravenous regional treatment (Jelinek et al. 1991).

The authors thank Wenche Aaslund for technical assistance. The project was supported by Stiftelsen för Bistånd åt Rörelsehindrade i Skåne and by the Medical Faculty of Lund University.

No competing interests declared.


